Early low‐dose rituximab for active thyroid eye disease: An effective and well‐tolerated treatment

Abstract

Low-dose rituximab is an efficacious, well-tolerated and safe treatment for active TED; reducing disease activity and allowing reduced administration of systemic steroid.